GlassScriptPhysician profile
Diana E Hansell
NPI 1417931098
$2,760.90
in general payments reported to CMS, 2019-2025
27 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $423 · 2022: $490 · 2023: $686 · 2024: $740 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.97 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $296.65 | 2021-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $289.08 | 2022-2025 | |
| Pfizer INC. | $254.70 | 2021-2025 | |
| Glaxosmithkline, LLC. | $224.07 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $206.53 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $194.11 | 2021-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $185.07 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $114.05 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $93.21 | 2023-2025 | Capvaxive, Gardasil 9, Verquvo |
| Exact Sciences Corporation | $67.26 | 2023 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $63.41 | 2023-2025 | Keveyis |
| Sumitomo Pharma America, INC. | $60.60 | 2023-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $56.96 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $50.25 | 2024-2025 | Nuzyra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $41.14 | 2024 | Watchman Flx |
| Abbvie INC. | $40.40 | 2023 | |
| Philips North America LLC | $39.76 | 2024 | (Cm9) Amb Mon & Diag Und |
| Edwards Lifesciences Corporation | $27.49 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Radius Health, INC. | $26.11 | 2023 | Tymlos |
| Shield Therapeutics INC | $24.99 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $22.44 | 2021 | |
| Optinose US, INC. | $20.65 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.76 | 2021 | |
| Corcept Therapeutics | $16.38 | 2022 | |
| Insmed, INC. | $14.77 | 2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $13.09 | 2023 | Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Hansell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.